PIB Tracker137 anti-cancer drugs, margins capped at 30 per cent from 9 November
The pricing authority has notified the list the Cabinet decision of 8 October promised, with maximum retail prices expected to fall by up to 70 per cent.
What happened
- The NPPA notified Trade Margin Rationalisation on 137 non-scheduled anti-cancer drugs, capping the trade margin at 30 per cent of MRP under Paragraph 19 of the DPCO, 2013.
- Gazette notification dated 17 October 2026; revised prices effective 9 November 2026; MRPs expected to fall by up to 70 per cent.
- The list - recommended by an expert committee under the DGHS and to be updated periodically - includes immunotherapy drugs for over 20 cancer types, Denosumab, Pegfilgrastim, Bevacizumab, Pembrolizumab, Durvalumab and Osimertinib.
- Compliance: manufacturers report revised prices within seven days and publish price lists; retailers and hospitals must charge and display reduced prices from 9 November; hospitals must post them online.
- Precedent: the 2019 pilot capped margins on 42 anti-cancer drugs and reduced the MRP of 526 brands by up to 90 per cent. Verification is via the Pharma Sahi Daam app, enforcement by State Drug Controllers.
For Prelims
- Scheduled versus non-scheduled: drugs in Schedule I of the DPCO, 2013 - drawn from the National List of Essential Medicines - get a government ceiling price. Non-scheduled drugs are free to be priced, subject only to a 10 per cent annual increase limit, which is why a margin cap is the available tool.
- Paragraph 19 of the DPCO: the extraordinary power to fix or revise the price of any drug in public interest, outside the normal ceiling-price machinery. It is the provision under which both the 2019 pilot and this order were issued.
- What a trade margin is: the difference between the price at which the manufacturer sells to the distributor and the MRP paid by the patient. Capping it at 30 per cent of MRP squeezes the distribution chain rather than the manufacturer’s own price.
- NPPA: established in 1997 under the Department of Pharmaceuticals, it fixes and revises prices, monitors compliance and recovers overcharged amounts; the DPCO derives its authority from the Essential Commodities Act, 1955.
- Why cancer drugs specifically: the Authority’s market analysis found average mark-ups of about 170 per cent on non-scheduled anti-cancer medicines, reaching 700 per cent in some cases, with savings to patients estimated at Rs 2,500 crore a year when the cap was approved on 8 October.
- The drug classes named: Pembrolizumab and Durvalumab are immune checkpoint inhibitors, Osimertinib a targeted therapy for a lung cancer mutation, Bevacizumab an anti-angiogenic antibody, Denosumab acts on bone metastasis and Pegfilgrastim raises white cell counts after chemotherapy - all biologics or targeted drugs, the most expensive segment of cancer care.
- Out-of-pocket spending: cancer is a classic catastrophic-expenditure illness, and drug cost is the share insurance packages cover least well - which is why price control reaches patients that PM-JAY package rates do not.
- Enforcement is with the States: State Drug Controllers police compliance by manufacturers, retailers and hospitals, and overcharging is recovered with interest under the DPCO - the step at which previous price orders have leaked.
For UPSC: This completes a policy cycle that began with a Cabinet decision nine days earlier, and it is the cleanest available example of regulating a market through margins rather than prices. Deploy it on access to medicines and out-of-pocket health expenditure, on price regulation and its instruments, and on the Centre-State division in enforcement.
What it is NOT: No list of the 137 drugs in the release, and no brand-level price table, so the up-to-70 per cent claim cannot be checked against any specific medicine. No estimate of total patient savings from this order - the Rs 2,500 crore figure came with the October decision and is not repeated. Nothing on how many of the 137 are under patent and how many have biosimilars, which determines whether a margin cap or competition is doing the work. No compliance data from the 2019 pilot beyond the price fall, and no statement of what happened to availability - the standard industry objection to margin caps is that distributors stop stocking, and the release does not address it.
For Mains
Syllabus: GS2.13 · GS2.10 · Linkage L1
Anchor
The National Pharmaceutical Pricing Authority has capped trade margins at 30 per cent of maximum retail price on 137 non-scheduled anti-cancer drugs, gazetted on 17 October and effective from 9 November, with prices expected to fall by up to 70 per cent.
Substantiation (data)
The order uses Paragraph 19 of the DPCO, 2013, on a list recommended by an expert committee under the Directorate General of Health Services, and covers immunotherapy drugs used in more than twenty cancers along with Denosumab, Pegfilgrastim, Bevacizumab, Pembrolizumab, Durvalumab and Osimertinib. The 2019 pilot on 42 drugs had reduced the prices of 526 brands by up to 90 per cent. Manufacturers must report revised prices within seven days; hospitals and retailers must charge and display them from 9 November.
Position
Attacking the margin rather than the price is the smarter intervention for drugs outside the essential-medicines list. A ceiling price sets what a manufacturer may charge and invites disputes about cost; a margin cap leaves the manufacturer’s price alone and removes the mark-up added between the factory and the patient, which the Authority’s own analysis found to average about 170 per cent. For a disease where the drug is bought at the hospital counter, that is where the money was going.
Counterpoint
Margin caps have a known failure mode: distributors and hospital pharmacies that can no longer earn on a drug may simply stop stocking it, and the release says nothing about availability monitoring. Nor does it publish the 137 names or any brand price, so the patient has no way to verify the reduction except through an app, and enforcement rests with State drug controllers whose record on earlier price orders is uneven.
Way forward
Publish the drug and brand-level price table, track availability at hospital pharmacies for a quarter after 9 November, and report compliance and recovery action by State. The periodic updating of the list is the mechanism to watch - it is what turns this from an order into a regime.
Conclusion
Nine days from Cabinet decision to gazette, and twenty-three to effect: the list is out, the lever is the margin, and the test now is whether the drugs stay on the shelf at the lower price.
Deploys into: Access to medicines and out-of-pocket expenditure · Price regulation instruments · Centre-State enforcement of drug prices · Catastrophic health spending
Ministry of Chemicals and Fertilizers · 2026-10-17 · PRID 2324743 · PIB source ↗